-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer’s sign (AD) is a degenerative disease of the central nervous system, most of which manifests as progressive cognitive dysfunction and behavioral impairment, but its etiology is not clear, and there is still no cure.
At present, the biomarkers and checkpoints for AD have made good progress.
On May 24, 2021, Oskar Hansson, Sebastian Palmqvist and other researchers from Lund University in Sweden jointly published an online publication entitled "Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures" in the journal Nature Medicine.
DOI: 10.
The research team recruited 340 patients with cognitive impairment through BioFINDER, with an average age of 70.
Baseline characteristics included in the cohort study
In order to screen out the best model for predicting AD dementia, the research team conducted a data-driven model selection
Predicting the model selection process and performance of Alzheimer's disease dementia within 4 years
Studies have found that plasma P-tau217 can accurately predict AD in BioFINDER
Cross-validation and implementation of various algorithms
In conclusion, this article shows that plasma P-τ, combined with a brief cognitive test and APOE genotyping, may greatly improve the diagnosis of Alzheimer's disease and promote the recruitment of Alzheimer's disease trials
Reference materials:
[1] https://doi.
